Separate indirect from direct design evidence (SIDDE)

Fixed effects model: 

            comparison k  nma direct indir. RoR z p-value
 lemborexant:melatonin 0 0.28      .   0.28   . .       .
   lemborexant:placebo 2 1.41   1.41      .   . .       .
 lemborexant:ramelteon 0 1.20      .   1.20   . .       .
  lemborexant:zaleplon 0 0.47      .   0.47   . .       .
  lemborexant:zolpidem 0 0.41      .   0.41   . .       .
     melatonin:placebo 1 5.06   5.06      .   . .       .
   melatonin:ramelteon 0 4.32      .   4.32   . .       .
    melatonin:zaleplon 0 1.68      .   1.68   . .       .
    melatonin:zolpidem 0 1.49      .   1.49   . .       .
     ramelteon:placebo 1 1.17   1.17      .   . .       .
      zaleplon:placebo 1 3.02   2.42      .   . .       .
      zolpidem:placebo 3 3.39   3.50      .   . .       .
    ramelteon:zaleplon 0 0.39      .   0.39   . .       .
    ramelteon:zolpidem 0 0.35      .   0.35   . .       .
     zaleplon:zolpidem 1 0.89   0.98      .   . .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
[1] "Percent of comparisons where there is some evidence (p-value<0.05) of disagreement between direct and indirect sources: NaN. (0 out of 0 comparisons)."
[1] "File created by E. G. Ostinelli on 2022-01-01"
